148 related articles for article (PubMed ID: 2877701)
1. Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration.
De Cuyper H; Bollen J; van Praag HM; Verstraeten D
Br J Psychiatry; 1986 May; 148():560-6. PubMed ID: 2877701
[TBL] [Abstract][Full Text] [Related]
2. A loading-dose strategy for converting from oral to depot haloperidol.
Ereshefsky L; Toney G; Saklad SR; Anderson C; Seidel D
Hosp Community Psychiatry; 1993 Dec; 44(12):1155-61. PubMed ID: 7907570
[TBL] [Abstract][Full Text] [Related]
3. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of the efficacy of haloperidol decanoate in the treatment of chronic psychotic hospital patients].
Marchant N; Caruso S; Cuervo L; Brizuela A
Acta Psiquiatr Psicol Am Lat; 1985 Mar; 31(1):37-41. PubMed ID: 2864788
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the efficacy of haloperidol decanoate].
Alvarez JV; Li Gambi M
Acta Psiquiatr Psicol Am Lat; 1986 Sep; 32(3):233-6. PubMed ID: 2884807
[TBL] [Abstract][Full Text] [Related]
7. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study.
Deberdt R; Elens P; Berghmans W; Heykants J; Woestenborghs R; Driesens F; Reyntjens A; van Wijngaarden I
Acta Psychiatr Scand; 1980 Oct; 62(4):356-63. PubMed ID: 7468294
[TBL] [Abstract][Full Text] [Related]
8. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
[TBL] [Abstract][Full Text] [Related]
9. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.
Vasavan Nair NP; Suranyi-Cadotte B; Schwartz G; Thavundayil JX; Achim A; Lizondo E; Nayak R
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):30S-37S. PubMed ID: 3514689
[TBL] [Abstract][Full Text] [Related]
10. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
Youssef HA
Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
[TBL] [Abstract][Full Text] [Related]
11. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
12. [Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
Lemperiere T; Ropert R; Leger JM; Alexandre JY; Clerc G; Darondel A; Delaunay J; Delteil P; Malauzat D; Raynaud J
Encephale; 1984; 10(5):217-22. PubMed ID: 6519017
[TBL] [Abstract][Full Text] [Related]
13. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
14. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
Eklund K; Forsman A
Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.
Gelders YG
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-11. PubMed ID: 3559159
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
[TBL] [Abstract][Full Text] [Related]
17. [Open clinical trial with haloperidol decanoate in patients with psychotic disorders].
Ellerman LA
Acta Psiquiatr Psicol Am Lat; 1987 Jun; 33(2):157-62. PubMed ID: 3321918
[TBL] [Abstract][Full Text] [Related]
18. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting.
Foster S; Kessel J; Berman ME; Simpson GM
Int Clin Psychopharmacol; 1997 May; 12(3):175-9. PubMed ID: 9248875
[TBL] [Abstract][Full Text] [Related]
20. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.
Beresford R; Ward A
Drugs; 1987 Jan; 33(1):31-49. PubMed ID: 3545764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
